Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALUR NASDAQ:FEMY NASDAQ:GCTK NASDAQ:NXL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.16-2.7%$2.64$1.98▼$22.25$17.23M-0.4570,012 shs32,837 shsFEMYFemasys$0.36-0.4%$0.81$0.31▼$1.80$11.62M-2.581.33 million shs988,593 shsGCTKGlucoTrack$4.22-1.9%$6.02$4.22▼$3,756.00$3.87M-0.1938,742 shs16,159 shsNXLNexalin Technology$0.96+4.2%$0.98$0.59▼$4.49$15.99M3.692.79 million shs378,271 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies-2.70%-3.91%-20.88%-19.40%-86.28%FEMYFemasys-0.45%-37.81%-57.22%-59.65%-66.18%GCTKGlucoTrack-1.86%-23.69%-33.54%-44.18%-99.87%NXLNexalin Technology+4.19%-6.25%-7.16%-20.25%+2.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALURAllurion Technologies2.4533 of 5 stars3.45.00.00.00.01.70.6FEMYFemasys3.0429 of 5 stars3.53.00.00.03.02.50.6GCTKGlucoTrack0.4721 of 5 stars0.02.00.00.02.70.80.6NXLNexalin Technology2.9703 of 5 stars3.55.00.00.02.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALURAllurion Technologies 2.80Moderate Buy$22.83957.10% UpsideFEMYFemasys 3.00Buy$7.331,965.15% UpsideGCTKGlucoTrack 0.00N/AN/AN/ANXLNexalin Technology 3.00Buy$5.00422.85% UpsideCurrent Analyst Ratings BreakdownLatest GCTK, FEMY, ALUR, and NXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025ALURAllurion TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.006/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$32.11M0.52N/AN/A($8.24) per share-0.26FEMYFemasys$1.89M6.13N/AN/A$0.05 per share7.10GCTKGlucoTrackN/AN/AN/AN/A$7.65 per shareN/ANXLNexalin Technology$174.81K95.28N/AN/A$0.34 per share2.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$7.20M-$12.53N/AN/AN/A-158.30%N/A-59.91%11/12/2025 (Estimated)FEMYFemasys-$18.82M-$0.86N/AN/AN/A-1,113.72%-713.74%-152.60%11/11/2025 (Estimated)GCTKGlucoTrack-$22.60M-$56.60N/A∞N/AN/AN/A-352.05%N/ANXLNexalin Technology-$7.61M-$0.76N/A∞N/A-5,057.14%-209.20%-186.87%N/ALatest GCTK, FEMY, ALUR, and NXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025ALURAllurion Technologies-$0.65-$0.57+$0.08-$1.28$6.20 million$3.38 million8/14/2025Q2 2025GCTKGlucoTrackN/A-$9.62N/A-$9.62N/AN/A8/8/2025Q2 2025FEMYFemasys-$0.18-$0.16+$0.02-$0.16$0.80 million$0.41 million8/6/2025Q2 2025NXLNexalin Technology-$0.14-$0.10+$0.04-$0.10$0.04 million$0.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/AGCTKGlucoTrackN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A2.021.70FEMYFemasys0.030.890.41GCTKGlucoTrack0.033.273.27NXLNexalin TechnologyN/A10.4310.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%FEMYFemasys65.27%GCTKGlucoTrack10.92%NXLNexalin Technology0.65%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies22.40%FEMYFemasys11.54%GCTKGlucoTrack12.91%NXLNexalin Technology25.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies5017.76 million5.79 millionOptionableFEMYFemasys3032.58 million28.82 millionNot OptionableGCTKGlucoTrack5899,000783,000Not OptionableNXLNexalin Technology317.42 million13.02 millionNot OptionableGCTK, FEMY, ALUR, and NXL HeadlinesRecent News About These CompaniesNexalin Technology, Inc. Announces Investor Webinar to Showcase Innovative DIFS™ Technology for Mental Health SolutionsAugust 25, 2025 | quiverquant.comQJoin Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9August 25, 2025 | markets.businessinsider.comJoin Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9August 25, 2025 | globenewswire.comNexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic InitiativesAugust 1, 2025 | taiwannews.com.twTNexalin Technology appoints Justin Van Fleet as CFOAugust 1, 2025 | msn.comNexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic InitiativesAugust 1, 2025 | globenewswire.comNexalin and FatPipe Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVMay 30, 2025 | usatoday.comNexalin Technology, Inc.: Strategic Advancements and Financial Stability Justify Buy RatingMay 29, 2025 | tipranks.comJoin Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3May 28, 2025 | finance.yahoo.comNexalin Technology, Inc. to Host Investor Webinar Showcasing Innovative Neurostimulation Advances on June 3, 2025May 28, 2025 | quiverquant.comQJoin Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3May 28, 2025 | globenewswire.comNexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging DataMay 13, 2025 | finance.yahoo.comNexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging DataMay 13, 2025 | globenewswire.comNexalin Technology, Inc. Closes Public Offering of 3,850,000 Shares at $1.30 Per Share, Raising $5.0 MillionMay 6, 2025 | quiverquant.comQNexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public OfferingMay 6, 2025 | globenewswire.comNexalin Technology Announces Pricing of $5.0 Million Public Offering of Common StockMay 5, 2025 | globenewswire.comNexalin Technology, Inc. Plans Q-Submission to FDA for Gen-2 SYNC System Targeting Cognitive DisordersMay 1, 2025 | quiverquant.comQNexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA FeedbackMay 1, 2025 | globenewswire.comNexalin Technology receives IRB approval in Brazil, begins trialApril 24, 2025 | markets.businessinsider.comNexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and InsomniaApril 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGCTK, FEMY, ALUR, and NXL Company DescriptionsAllurion Technologies NYSE:ALUR$2.16 -0.06 (-2.70%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$2.17 +0.01 (+0.69%) As of 08/29/2025 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.Femasys NASDAQ:FEMY$0.36 0.00 (-0.45%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.36 +0.00 (+0.82%) As of 08/29/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.GlucoTrack NASDAQ:GCTK$4.22 -0.08 (-1.86%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$4.30 +0.08 (+1.90%) As of 08/29/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.Nexalin Technology NASDAQ:NXL$0.96 +0.04 (+4.19%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$0.94 -0.01 (-1.39%) As of 08/29/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
